Head-To-Head Comparison: Dr.Reddy’s Laboratories (NYSE:RDY) vs. Guardion Health Sciences (NYSE:GHSI)

Guardion Health Sciences (NASDAQ:GHSI) and Dr.Reddy’s Laboratories (NYSE:RDY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Guardion Health Sciences and Dr.Reddy’s Laboratories, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Guardion Health Sciences 0 0 0 0 N/A
Dr.Reddy’s Laboratories 1 2 1 0 2.00

Dr.Reddy’s Laboratories has a consensus price target of $39.00, indicating a potential upside of 5.21%. Given Dr.Reddy’s Laboratories’ higher possible upside, analysts clearly believe Dr.Reddy’s Laboratories is more favorable than Guardion Health Sciences.

Dividends

Dr.Reddy’s Laboratories pays an annual dividend of $0.27 per share and has a dividend yield of 0.7%. Guardion Health Sciences does not pay a dividend. Dr.Reddy’s Laboratories pays out 16.5% of its earnings in the form of a dividend.

Profitability

This table compares Guardion Health Sciences and Dr.Reddy’s Laboratories’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Guardion Health Sciences N/A N/A N/A
Dr.Reddy’s Laboratories 12.20% 13.85% 8.13%

Institutional and Insider Ownership

12.8% of Dr.Reddy’s Laboratories shares are owned by institutional investors. 2.0% of Dr.Reddy’s Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Guardion Health Sciences and Dr.Reddy’s Laboratories’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Guardion Health Sciences $940,000.00 38.16 -$7.77 million N/A N/A
Dr.Reddy’s Laboratories $2.23 billion 2.77 $272.00 million $1.64 22.60

Dr.Reddy’s Laboratories has higher revenue and earnings than Guardion Health Sciences.

Summary

Dr.Reddy’s Laboratories beats Guardion Health Sciences on 10 of the 12 factors compared between the two stocks.

About Guardion Health Sciences

Guardion Health Sciences, Inc., a specialty health sciences company, develops, formulates, and distributes condition-specific medical foods in the United States and internationally. It operates in two segments, Medical Foods and Vision Testing Diagnostics. The Medical Foods segment offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; MapcatSF, a medical device that measures the macular pigment optical density; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. The Vision Testing Diagnostics segment develops, manufactures, and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, real-world vision evaluation, and industrial vision testing. Its products include VectorVision CSV-1000, an instrument for contrast sensitivity testing; and ESV-3000 ETDRS, a device for early treatment diabetic retinopathy study in visual acuity testing. The company distributes its products through direct sales force, as well as through its guardionhealth.com Website. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in San Diego, California.

About Dr.Reddy’s Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. It also provides a portfolio of in-licensed dermatology products. As of March 31, 2018, this segment had 13 active products development programs pipeline that are in various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, pain management, oncology, dermatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.